These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 24403823)

  • 1. Rituximab for the treatment of rheumatoid arthritis: an update.
    Mok CC
    Drug Des Devel Ther; 2013 Dec; 8():87-100. PubMed ID: 24403823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of intravenous immunoglobulin to treat chronic bilateral otomastoiditis in the setting of rituximab induced hypogammaglobulinemia.
    Otremba MD; Adam SI; Price CC; Hohuan D; Kveton JF
    Am J Otolaryngol; 2012; 33(5):619-22. PubMed ID: 22361345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. B-cell therapies in established rheumatoid arthritis.
    Leandro MJ; Becerra-Fernandez E
    Best Pract Res Clin Rheumatol; 2011 Aug; 25(4):535-48. PubMed ID: 22137923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of hospitalised infection in rheumatoid arthritis patients receiving biologics following a previous infection while on treatment with anti-TNF therapy.
    Yun H; Xie F; Delzell E; Chen L; Levitan EB; Lewis JD; Saag KG; Beukelman T; Winthrop K; Baddley JW; Curtis JR
    Ann Rheum Dis; 2015 Jun; 74(6):1065-71. PubMed ID: 24608404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: results from a randomized controlled trial.
    Greenwald MW; Shergy WJ; Kaine JL; Sweetser MT; Gilder K; Linnik MD
    Arthritis Rheum; 2011 Mar; 63(3):622-32. PubMed ID: 21360491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. B-cell therapies for rheumatoid arthritis.
    Scher JU
    Bull NYU Hosp Jt Dis; 2012; 70(3):200-3. PubMed ID: 23259629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Safety of rituximab in patients with rheumatoid arthritis].
    Morović-Vergles J
    Reumatizam; 2010; 57(2):158-60. PubMed ID: 21875022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Rituximab].
    Feist E; Dörner T
    Z Rheumatol; 2010 Sep; 69(7):594-600. PubMed ID: 20694729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis.
    Buch MH; Smolen JS; Betteridge N; Breedveld FC; Burmester G; Dörner T; Ferraccioli G; Gottenberg JE; Isaacs J; Kvien TK; Mariette X; Martin-Mola E; Pavelka K; Tak PP; van der Heijde D; van Vollenhoven RF; Emery P;
    Ann Rheum Dis; 2011 Jun; 70(6):909-20. PubMed ID: 21378402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. B cell-targeted therapy for rheumatoid arthritis: an update on the evidence.
    Looney RJ
    Drugs; 2006; 66(5):625-39. PubMed ID: 16620141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Rituximab in rheumatoid arthritis: a systematic review of efficacy and safety].
    Hernández-Cruz B; García-Arias M; Ariza Ariza R; Martín Mola E
    Reumatol Clin; 2011; 7(5):314-22. PubMed ID: 21925447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation.
    Malottki K; Barton P; Tsourapas A; Uthman AO; Liu Z; Routh K; Connock M; Jobanputra P; Moore D; Fry-Smith A; Chen YF
    Health Technol Assess; 2011 Mar; 15(14):1-278. PubMed ID: 21439251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of the FcGRIIIa polymorphism in modifying the association between treatment and outcome in patients with rheumatoid arthritis treated with rituximab versus TNF-α antagonist therapies.
    Sarsour K; Greenberg J; Johnston JA; Nelson DR; O'Brien LA; Oddoux C; Ostrer H; Pearlman A; Reed G
    Clin Exp Rheumatol; 2013; 31(2):189-94. PubMed ID: 23294992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple courses of rituximab produce sustained clinical and radiographic efficacy and safety in patients with rheumatoid arthritis and an inadequate response to 1 or more tumor necrosis factor inhibitors: 5-year data from the REFLEX study.
    Keystone EC; Cohen SB; Emery P; Kremer JM; Dougados M; Loveless JE; Chung C; Wong P; Lehane PB; Tyrrell H
    J Rheumatol; 2012 Dec; 39(12):2238-46. PubMed ID: 23027887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of a third tumor necrosis factor-α-blocking agent compared with rituximab after failure of 2 TNF-blocking agents in rheumatoid arthritis.
    Blom M; Kievit W; Donders AR; den Broeder AA; Straten VH; Kuper I; Visser H; Jansen TL; Brus HL; Branten AJ; van de Laar MA; van Riel PL
    J Rheumatol; 2011 Nov; 38(11):2355-61. PubMed ID: 21885487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tuberculosis risk in patients treated with non-anti-tumor necrosis factor-α (TNF-α) targeted biologics and recently licensed TNF-α inhibitors: data from clinical trials and national registries.
    Cantini F; Niccoli L; Goletti D
    J Rheumatol Suppl; 2014 May; 91():56-64. PubMed ID: 24789001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Newer biological agents in the treatment of rheumatoid arthritis: do the benefits outweigh the risks?
    Nurmohamed MT
    Drugs; 2009 Oct; 69(15):2035-43. PubMed ID: 19791825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The anti-CD20 antibody rituximab reduces the Th17 cell response.
    van de Veerdonk FL; Lauwerys B; Marijnissen RJ; Timmermans K; Di Padova F; Koenders MI; Gutierrez-Roelens I; Durez P; Netea MG; van der Meer JW; van den Berg WB; Joosten LA
    Arthritis Rheum; 2011 Jun; 63(6):1507-16. PubMed ID: 21400475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of response to rituximab in patients with active rheumatoid arthritis and inadequate response to anti-TNF agents or traditional DMARDs.
    Narvaez J; Díaz-Torné C; Ruiz JM; Hernandez MV; Torrente-Segarra V; Ros S; Rodriguez de la Serna A; Díaz-López C; Sanmartí R; Nolla JM
    Clin Exp Rheumatol; 2011; 29(6):991-7. PubMed ID: 22133052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Rituximab in patients with rheumatoid arthritis: systematic review].
    Brodszky V; Czirják L; Géher P; Hodinka L; Kárpáti K; Péntek M; Poór G; Szekanecz Z; Gulácsi L
    Orv Hetil; 2007 Oct; 148(40):1883-93. PubMed ID: 17905683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.